approval of this information collection; they also will become a matter of public record.

Dated: June 30, 2004.

Gwellnar Banks,

Management Analyst, Office of the Chief Information Officer.

[FR Doc. 04–15401 Filed 7–6–04; 8:45 am] **BILLING CODE 3510–22–S**

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

[I.D. 070104I]

Proposed Information Collection; Comment Request; Coastal Zone Management Program Administration

AGENCY: National Oceanic and Atmospheric Administration (NOAA). **ACTION:** Notice.

SUMMARY: The Department of Commerce, as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to take this opportunity to comment on proposed and/or continuing information collections, as required by the Paperwork Reduction Act of 1995, Public Law 104–13 (44 U.S.C. 3506(c)(2)(A)).

DATES: Written comments must be submitted on or before September 7, 2004.

ADDRESSES: Direct all written comments to Diana Hynek, Departmental Paperwork Clearance Officer, Department of Commerce, Room 6625, 14th and Constitution Avenue, NW, Washington, DC 20230 (or via the Internet at dHynek@doc.gov).

FOR FURTHER INFORMATION CONTACT:

Requests for additional information or copies of the information collection instrument and instructions should be directed to Masi Okasaki, 301–713–3155, extension 185 or e-mail at masi.okasaki@noaa.gov.

SUPPLEMENTARY INFORMATION:

I. Abstract

The coastal zone management grants provide funds to states and territories to implement federally-approved coastal management plans; revise assessment document and multi-year strategy; submit Section 306A documentation on the approved coastal zone management plans; submit requests to approve amendments or program changes; and complete the state's coastal nonpoint source pollution program.

II. Method of Collection

Information for Performance Reports is collected according to the Performance Report Guideline; Assessment and Strategy documents is collected according to the Assessment and Strategy Guidelines; Section 306A documentation is collected according to the Section 306A Guidance; Amendment or program changes is collected according to the Final Program Change Guidance; and Coastal Nonpoint Source Pollution Program document is collected according to guidance specifying management measures for sources of nonpoint pollution in coastal waters and coastal nonpoint pollution control program, program development and approval guidance.

III. Data

OMB Number: 0648-0119.

Form Number: None.

Type of Review: Regular submission.

Affected Public: State, Local and Tribal Government.

Estimated Number of Respondents: 34.

Estimated Time Per Response:
Performance Reports 27 hours;
Assessment and Strategy 240 hours;
306A documentation - 5 hours;
Amendments and Routine Program
Changes 8 hours; and 6,217 Nonpoint
Pollution Control Program 150 hours.

Estimated Total Annual Burden Hours: 6,598 hours.

Estimated Total Annual Cost to Public: \$450.

IV. Request for Comments

Comments are invited on: (a) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden (including hours and cost) of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

Comments submitted in response to this notice will be summarized and/or included in the request for OMB approval of this information collection; they also will become a matter of public record. Dated: June 30, 2004.

Gwellnar Banks,

Management Analyst, Office of the Chief Information Officer.

[FR Doc. 04–15402 Filed 7–6–04; 8:45 am] BILLING CODE 3510–08–S

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

[I.D. 062904E]

Pacific Fishery Management Council; Public Hearings

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Notice of public hearings.

SUMMARY: The Pacific Fishery Management Council (Council) and NMFS will hold two public scoping hearings on alternatives and impacts to be included in an environmental impact statement (EIS) on dedicated access privileges for the Pacific Coast groundfish trawl fishery.

DATES: The hearings will be held Tuesday, July 20, 2004, at 3 p.m. and Tuesday, July 27, 2004, at 3:30 p.m. ADDRESSES: The hearings will be held respectively at the Jim Traynor Conference Room, Building 4, 7600 Sand Point Way, Seattle, WA 98115; telephone: (206) 526–4490 and in the Auditorium of the Mark O. Hatfield Marine Science Center, 2030 S. Marine Science Drive, Newport, OR 97365; telephone: (541) 867–0212.

FOR FURTHER INFORMATION CONTACT: Jim Seger, Staff Officer (Economist); Pacific Fishery Management Council, 7700 NE Ambassador Place, Suite 200, Portland, OR 97220–1384; telephone (503) 820–2280.

SUPPLEMENTARY INFORMATION: The Council and NMFS announced their intent to hold public scoping meetings on May 24, 2004, (69 FR 29482-29485) when the Council and NMFS issued their notice of intent to prepare an EIS on dedicated access privileges for the Pacific Coast groundfish trawl fishery. The first scoping meeting was held June 13, 2004, in conjunction with a Council meeting in Foster City, CA. The purpose of these hearings is to identify alternatives to be considered and the notable impacts that should be evaluated. These scoping hearings are not intended as a forum for comments in favor of or opposed to the alternatives. A scoping information pamphlet and detailed public scoping

information document are available from the Council website (www.pcouncil.org) or on request from the Council office (see ADDRESSES).

The hearings will be restricted to those issues specifically listed in this document.

Special Accommodations

The meeting is physically accessible to people with disabilities. Requests for sign language interpretation or other auxiliary aids should be directed to Ms. Carolyn Porter at (503) 820–2280 at least 5 days prior to the meeting date.

Dated: July 1, 2004.

Alan D. Risenhoover,

Acting Director, Office of Sustainable Fisheries, National Marine Fisheries Service. [FR Doc. E4–1487 Filed 7–6–04; 8:45 am] BILLING CODE 3510–22–8

DEPARTMENT OF COMMERCE

Patent and Trademark Office

[Docket No. 2004-P-039]

Grant of Interim Extension of the Term of U.S. Patent No. 4,591,585; Atamestane

AGENCY: United States Patent and Trademark Office.

ACTION: Notice of interim patent term extension.

SUMMARY: The United States Patent and Trademark Office has issued a certificate under 35 U.S.C. 156(d)(5) for a one-year interim extension of the term of U.S. Patent No. 4,591,585.

FOR FURTHER INFORMATION CONTACT:

Karin Ferriter by telephone at (703) 306–3159; by mail marked to her attention and addressed to the Commissioner for Patents, Mail Stop Patent Ext., P.O. Box 1450, Alexandria, VA 22313–1450; by fax marked to her attention at (703) 872–9411, or by e-mail to Karin.Ferriter@uspto.gov.

SUPPLEMENTARY INFORMATION: Section 156 of title 35, United States Code, generally provides that the term of a patent may be extended for a period of up to five years if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review, and that the patent may be extended for interim periods of up to a year if the regulatory review is anticipated to extend beyond the expiration date of the patent.

On May 21, 2004, patent owner Schering Aktiengesellschaft, timely filed an application under 35 U.S.C. 156(d)(5) for an interim extension of the term of U.S. Patent No. 4,591,585. The patent claims the product atamestane. The application indicates that a New Drug Application for the human drug product atamestane has been filed and is currently undergoing regulatory review before the Food and Drug Administration for permission to market

Administration for permission to market or use the product commercially.

Review of the application indicates that except for permission to market or use the product commercially, the subject patent would be eligible for an extension of the patent term under 35 U.S.C. 156, and that the patent should be extended for one year as required by 35 U.S.C. 156(d)(5)(B). Since it is apparent that the regulatory review period will continue beyond the expiration date of the patent (June 18, 2004), interim extension of the patent term under 35 U.S.C. 156(d)(5) is appropriate.

An interim extension under 35 U.S.C. § 156(d)(5) of the term of U.S. Patent No. 4,591,585 is granted for a period of one year from the expiration date of the patent, *i.e.*, until June 18, 2005.

Dated: June 24, 2004.

Jon W. Dudas,

Acting Under Secretary of Commerce for Intellectual Property and Acting Director of the United States Patent and Trademark Office.

[FR Doc. 04–15270 Filed 7–6–04; 8:45 am] BILLING CODE 3510–16–P

DEPARTMENT OF COMMERCE

Patent and Trademark Office

[Docket No. 2004-P-041]

Grant of Second Interim Extension of the Term of U.S. Patent No. 4,585,597; Ecamsule

AGENCY: United States Patent and Trademark Office, Commerce.

ACTION: Notice of interim patent term extension.

SUMMARY: The United States Patent and Trademark Office has issued a certificate under 35 U.S.C. 156(d)(5) for a second one-year interim extension of the term of U.S. Patent No. 4,585,597.

FOR FURTHER INFORMATION CONTACT:

Karin Ferriter by telephone at (703) 306–3159; by mail addressed to Mail Stop Patent Ext., Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313–1450; by fax at (703) 872–9411, or by e-mail to Karin.Ferriter@uspto.gov.

SUPPLEMENTARY INFORMATION: Section 156 of title 35, United States Code, generally provides that the term of a patent may be extended for a period of

up to five years if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review, and that the patent may be extended for interim periods of up to a year if the regulatory review is anticipated to extend beyond the expiration date of the patent.

On April 30, 2004, patent owner, L'Oreal S.A., timely filed an application under 35 U.S.C. 156(d)(5) for a second interim extension of the term of U.S. Patent No. 4,585,597. The patent claims the active ingredient MexorylTMSX (ecamsule) in the human drug product ANTHÉLIOSTMSP, a method of use of the ecamsule, and a method of manufacturing ecamsule. The application indicates, and the Food and Drug Administration has confirmed, that a New Drug Application for the human drug product ANTHÉLIOSTMSP (ecamsule) has been filed and is currently undergoing regulatory review before the Food and Drug Administration for permission to market or use the product commercially. The patent was previously extended for a term of one year.

Review of the application indicates that, except for permission to market or use the product commercially, the subject patent would be eligible for an extension of the patent term under 35 U.S.C. 156. Since it is apparent that the regulatory review period will continue beyond the extended expiration date of the patent (June 16, 2004), the term of the patent is extended under 35 U.S.C. 156(d)(5) for an additional term of one year, *i.e.*, until June 16, 2005.

Dated: June 24, 2004.

Jon W. Dudas,

Acting Under Secretary of Commerce for Intellectual Property and Acting Director of the United States Patent and Trademark Office.

[FR Doc. 04–15272 Filed 7–6–04; 8:45 am] BILLING CODE 3510–16–P

DEPARTMENT OF COMMERCE

Patent and Trademark Office

[Docket No. 2004-P-040]

Grant of Interim Extension of the Term of U.S. Patent No. 4,600,706; Natamycin

AGENCY: United States Patent and Trademark Office.

ACTION: Notice of interim patent term extension.

SUMMARY: The United States Patent and Trademark Office has issued a certificate under 35 U.S.C. 156(d)(5) for